Axsome Therapeutics’ (AXSM) Equal Weight Rating Reaffirmed at Morgan Stanley

Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “equal weight” rating restated by investment analysts at Morgan Stanley in a note issued to investors on Thursday,Benzinga reports. They presently have a $204.00 price target on the stock, up from their prior price target of $196.00. Morgan Stanley’s price objective points to a potential upside of 19.51% from the stock’s previous close.

Other analysts have also issued research reports about the company. B. Riley assumed coverage on Axsome Therapeutics in a research report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 target price on the stock. Wells Fargo & Company dropped their price objective on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating for the company in a research note on Tuesday, November 4th. UBS Group increased their target price on Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a research note on Tuesday. Oppenheimer restated an “outperform” rating and set a $220.00 target price on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Finally, Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $192.35.

Axsome Therapeutics Trading Down 0.7%

NASDAQ AXSM opened at $170.69 on Thursday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The stock has a market capitalization of $8.60 billion, a P/E ratio of -36.55, a PEG ratio of 9.06 and a beta of 0.44. The firm’s 50-day moving average is $149.54 and its two-hundred day moving average is $127.07. Axsome Therapeutics has a 12 month low of $79.19 and a 12 month high of $184.40.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The company had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company’s revenue was up 63.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mark E. Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director owned 10,002 shares in the company, valued at approximately $1,652,130.36. This trade represents a 78.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Herriot Tabuteau sold 91,705 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $132.34, for a total value of $12,136,239.70. Following the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $956,685.86. This represents a 92.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 420,903 shares of company stock valued at $63,552,838. 22.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Versant Capital Management Inc lifted its position in shares of Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after purchasing an additional 203 shares during the last quarter. First Horizon Corp acquired a new stake in Axsome Therapeutics in the third quarter valued at $34,000. Optiver Holding B.V. lifted its holdings in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after buying an additional 130 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $38,000. Finally, Advisory Services Network LLC acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $40,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright raised 2026 earnings estimates substantially (Q2, Q3, Q4 and FY2026 to $3.72 EPS total) and reiterated a “Buy” rating with a $200 price target — this signals higher expected profitability and gives investors a near-term target above current levels.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can buoy demand for the shares. UBS Sticks to Their Buy Rating for Axsome Therapeutics
• Positive Sentiment: Market commentary highlights two late-2025 FDA developments — acceptance of a supplemental filing for AXS-05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS-12 (narcolepsy). Those regulatory moves expand potential indications and revenue runway, and underpin the bullish analyst view. Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
• Neutral Sentiment: Street positioning remains overwhelmingly positive (majority of analysts are Buy) and recent reiterations/price targets suggest upside, but consensus still reflects variability in timing and magnitude of revenue from new indications.
• Negative Sentiment: CEO insider sales — Herriot Tabuteau sold a combined 139,414 shares across Jan. 5–7 for roughly $23.88M in proceeds; after these trades the CEO directly owns 7,229 shares (a ~90%+ reduction in their position). Large, concentrated insider selling can create near‑term selling pressure and raise governance/optics concerns for some investors. SEC Filing — Insider Transactions

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.